Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models

Go back to Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Delayed: 1.38 -0.02 (1.43%)
Previous Close $1.40    52 Week High $3.50 
Open $1.38    52 Week Low $0.86 
Day High $1.41    P/E N/A 
Day Low $1.33    EPS $-7.61 
Volume 358,228